On January 6, 2022 Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, reported that it will present at the H.C. Wainwright BioConnect Virtual Conference, taking place on January 10-13, 2022 (Press release, Ayala Pharmaceuticals, JAN 6, 2022, View Source [SID1234598325]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available on the "Events and Presentations" section of the Ayala Pharmaceuticals website, beginning at 7:00 AM ET on Monday, January 10, 2022.